A 75-year-old woman with osteoporosis presented with a 2-year history of anterior thigh pain that was worse when standing and walking. She had taken alendronate for more than 20 years, which was replaced with annual zoledronic acid infusions for the last 3 years. On examination, she had an antalgic gait. The range of motion of her hips, knees and straight leg raise were normal. The results of a complete blood count and metabolic panel were normal, as were her levels of vitamin D, muscle enzymes and acute phase reactants. Her thyroid function was normal.
tures on the radiographs. She was advised to avoid bisphosphonates and start daily subcutaneous injections of teriparatide (recombinant parathyroid hormone). She underwent prophylactic fixation of both femurs with intra med ul lary nails.
Long-term use of bisphosphonates (especially alendronate) has been associated with subtro ch anter ic femoral cortical stress reaction. 1 The risk of atypical subtrochanteric fractures increases with the duration of bisphosphonate exposure. 1 Often there is prodromal pain for weeks to years.
1,2 In a case-control study, the incidence rate was quite low (32 cases per million person-years). 1 Other risk factors included age between 50 and 79 years, female sex and the use of vitamin D and glucocorticoids.
1 Bilateral fractures were frequent. A transverse fracture line through the hypertrophied lateral cortex of the femoral shaft is characteristic on radiographs. 1 The proposed mechanism is prolonged suppression of normal bone remodeling, with impaired repair of microfractures and increased bone fragility. 1 Atrophic nonunion is common.
Although the risk of atypical subtrochanteric fracture seems to rapidly diminish after stopping bisphosphonates, 2 the recommendation to discontinue use in patients with osteoporosis is controversial. Patients should be informed that the benefit of bisphosphonates appears to diminish after 5 years of continuous use, 3 and they should be cautioned about the increased risk of this potential complication.
